Could an HIV drug slow memory loss? small study explores new hope
NCT ID NCT06519357
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This pilot study tests whether lamivudine, an HIV medication, can reduce brain-damage markers in people with mild cognitive impairment (MCI) and signs of Alzheimer's. 23 participants aged 55-90 will take the drug for 24 weeks. The goal is to see if it lowers certain proteins in the blood linked to brain health and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Germans Trias I Pujol Hospital
Badalona, BARCELONA, 08916, Spain
Conditions
Explore the condition pages connected to this study.